Health Care & Life Sciences » Pharmaceuticals | Guizhou Xinbang Pharmaceutical Co. Ltd.

Guizhou Xinbang Pharmaceutical Co. Ltd. | Cash Flow

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
39,675.50
153,857.10
168,409.10
242,703.80
331,486.50
1,283,183.30
Depreciation, Depletion & Amortization
19,955.40
55,819.50
131,715.90
156,703.30
181,096.60
241,302.10
Other Funds
34,225.60
294,011.20
123,850.80
1,635,084.20
134,728.40
1,722,491.10
Funds from Operations
79,256.80
214,584.50
434,626.30
594,349.70
631,876.80
672,794.40
Changes in Working Capital
98,393.80
481,767.90
214,437.70
788,355.00
426,514.00
889,725.40
Net Operating Cash Flow
19,137.00
267,183.40
220,188.60
194,005.30
205,362.80
216,931
Capital Expenditures
44,801.00
282,637.50
492,478.10
432,231.30
435,028.70
Sale of Fixed Assets & Businesses
47.20
15,560.90
1,220.40
14,167.20
7,827.00
Purchase/Sale of Investments
426,500.00
91,933.60
7,107.00
241,978.00
9,646.00
Net Investing Cash Flow
139,099.20
378,641.40
454,653.60
596,668.10
437,060.30
Cash Dividends Paid - Total
-
15,013.60
29,431.30
51,946.90
51,146.90
Issuance/Reduction of Debt, Net
86,750.00
722,198.10
325,000.00
268,792.50
898,407.50
Net Financing Cash Flow
52,524.40
1,001,195.60
171,717.90
1,851,929.80
712,532.20
Net Change in Cash
105,711.80
355,370.80
62,747.10
1,069,715.30
470,793.30
Free Cash Flow
63,938.00
549,820.90
272,289.50
626,236.60
229,665.80
Deferred Taxes & Investment Tax Credit
149.10
1,691.80
2,792.80
14,294.40
8,560.30
7,815.50
Net Assets from Acquisitions
34,345.50
-
43,711.20
63,374.00
212.60
Other Sources
366,500.00
50,368.80
-
-
-
Exchange Rate Effect
-
-
-
8,458.80
10,041.50
Other Uses
-
70,000.00
-
-
-

About Guizhou Xinbang Pharmaceutical Co.

View Profile
Address
6/F, Garden No. 1, Kekai
Guiyang Guizhou 550018
China
Employees -
Website http://www.xinbang.com
Updated 07/08/2019
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its business segments include pharmaceutical production and development, medical services, and medicine distribution sectors. Its products include medicines for cardiovascular and cerebrovascular, digestive system, endocrine, blood system, and urinary system diseases.